Breaking News

Oncothyreon Restructures, Sells Stimuvax Site

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Oncothyreon Inc. has announced plans to restructure and focus on development of two compounds, PX-478 and PX-866. PX-478 is an inhibitor of hypoxia inducible factor-1 alpha that is currently in a Phase I trial for advanced metastatic cancer and lymphoma. PX-866 is an inhibitor of PI-3 kinase that is also in a Phase I trial in patients with advanced cancer. The company will reduce the size of its workforce and its senior management team. Approximately eight employees in its Edmonton facility, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters